The global follicular lymphoma treatment market is experiencing significant growth driven by advancements in targeted therapies and immunotherapies. Key industry leaders including F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., and Novartis AG are pioneering novel CD20-directed antibodies, bispecific antibodies, and CAR-T cell therapies that are transforming treatment paradigms and improving progression-free survival rates for patients with this indolent non-Hodgkin lymphoma subtype. Access Comprehensive Market Analysis: https://shorturl.at/l0iAr